Scientific Presentations

Oral Presentation at International Vaccines Congress Entitled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems” By Dr. Khursheed Anwer, Celsion’s CSO

Poster Presentation at Society of Gynecologic Oncology (SGO) Virtual Annual Meeting on Women’s Cancer_March 19-26, 2021

Expert Call – Ovarian Cancer Treatment Landscape and Emerging Opportunities Oppenheimer & Co. Inc. Conference Call

Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium Entitled “Phase I study of IL-12 plasmid administered in combination with NAC in patients with advanced stage ovarian cancer” by Dr. Premal H. Thaker, M.D., M.S.

Publication in Future Oncology – GEN-1 immunotherapy for the treatment of ovarian cancer, Premal H. Thaker, Nicholas Borys, Jason Fewell & Khursheed Anwer

Presentation at a company-sponsored Symposium- “Emerging Horizons in HCC: From Palliation to Cure” – at the International Liver Congress ™ 2018 entitled “Rethinking Our Approach to Intermediate-Size HCC” By Prof. Riccardo Lencioni, M.D., FSIR, EBIR.

KoL Lunch Presentation by Dr. Premal Thaker titled “Ovarian Cancer: New Horizons and Treatments”

Presentation at the American Association of Cancer Research (AACR) Special Conference entitled "Addressing Critical Questions in Ovarian Cancer Research and Treatment" by Dr. Khursheed Anwer, Celsion's executive vice president and chief scientific officer

Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Immunologic

Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Phase I st

Presentation at the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, IL by Dr. Haydar Celik, Ph.D. (NIH Clinical Center) entitled "RFA Duration per Tumor Volume May Correlate With Overall Surviva

Presentation at the 3rd Asian Conference on Tumor Ablation (ACTA) in Seoul, Korea by Professor Won Young Tak, M.D., Ph.D. entitled "Thermo-Sensitive Drug Assisted Ablation.

Presentation at the 2016 American Association of Cancer Research (AACR) Annual Meeting during the Drug Delivery Session by Dr. Jason Fewell entitled "Interlukin-12 Gene therapy in Combination with Bevacizumab and PEGylated Liposomal Doxorubicin for Treatm

Presentation at the 2015 San Antonio Breast Cancer Symposium during the New Drugs and Treatment Strategies Session by Dr. Hope Rugo entitled Lyso-Thermosensitive Liposomal Doxorubicin Shows Efficacy with Minimal Adverse Events in Patients with Breast Canc

Presentation Abstracts and Oral Presentation from the 2015 Asian Conference on Tumor Ablation (ACTA) in Fukuoka, Japan on October 30-31, 2015

Presentation at the International Liver Cancer Association 2015 Annual Conference on September 5, 2015 by Dr. Ghassan K. Abou-Alfa entitled "Intermediate HCC Treatment Paradigms and Lessons Learned."

Presentation at the International Liver Cancer Association 2015 Annual Conference on September 5, 2015 by Professor Riccardo Lencioni entitled "OPTIMA Phase III Clinical Trial: Study Design and Protocol."

Presentation at the International Liver Cancer Association 2015 Annual Conference on September 5, 2015 by Dr. Ronnie T.P. Poon entitled ""Current Management of Intermediate HCC: Unmet Medical Needs."

A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Pegylated Liposomal Doxorubicin) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Pr

Presentation at the Molecular Medicine TRI-Conference on February 20, 2015 by Dr. Khursheed Anwer titled "Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer."

Presentation at the International Liver Cancer Association 2014 Annual Conference on September 6, 2014 by Professor Ronnie T.P. Poon titled "New Paradigms in Staging HCC: BCLC vs. Hong Kong Liver Cancer Staging System (HKLS)"

Presentation at the International Liver Cancer Association 2014 Annual Conference on September 6, 2014 by Professor Riccardo Lencioni titled "Image Guided Ablations: Current Status and Future Prospects"

Presentation at the International Liver Cancer Association 2014 Annual Conference on September 6, 2014 by Dr. Richard Finn titled "Phase III Studies in Intermediate Stage HCC: What Have We Learned From Recent Failures"

Presentation at the 14th Annual Symposium on Therapeutic Ultrasound in Las Vegas, NV on April 5, 2014 by Dr. Mark Dewhirst – "Use of Thermosensitive Liposomes in Combination with Ultrasound"

Novel Targeted Therapy for Breast Cancer Chest Wall Recurrence Poster Presentation by Prof Hope S. Rugo, MD at the 2013 San Antonio Breast Cancer Conference.

Presentation at the 2013 International Liver Cancer Association (ILCA) Conference on September 14, 2013 by Professor Ronnie T.P. Poon, MD, PhD.

Presentation at The European Conference on Interventional Oncology (ECIO) by Professor Riccardo Lencioni, MD "New IO Approaches for HCC: An Update on Clinical Trials"

Presentation at The European Conference on Interventional Oncology (ECIO) by Professor Riccardo Lencioni, MD New Horizons: Thermally Sensitive Doxorubicin Carriers

Presentation at the World Conference on Interventional Oncology (WCIO) By Professor Riccardo Lencioni, MD "Advances in Image-Guided Ablation"

Presentation at the 2012 Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe by Professor Ronnie T.P. Poon "Thermosensitive Liposome in Combination with Thermal Ablation"